OctoPlus publishes prospectus for listing of shares
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED
STATES, CANADA, AUSTRALIA OR JAPAN
OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), today
publishes a prospectus for the admission to listing and trading on
Euronext Amsterdam by NYSE Euronext of 13,996,250 newly issued
ordinary shares as per 22 May 2009. The relevant shares were issued
in the context of the private placement and conversion of convertible
loans which OctoPlus announced on 19 February and closed on 25
February of this year. This prospectus was approved by the
Netherlands Authority for the Financial Markets (AFM) on 20 May 2009.
The prospectus is available in the Investor Relations section on the
Company's website: www.octoplus.nl.
For further information, please contact:
Rianne Roukema, Corporate Communications: telephone number +31 (71)
524 1071, or send an e-mail to Investor Relations at IR@octoplus.nl.
About OctoPlus
OctoPlus is a product-oriented biopharmaceutical company committed to
the creation of improved pharmaceutical products that are based on
OctoPlus' proprietary drug delivery technologies and have fewer side
effects, improved patient convenience and a better efficacy/safety
balance than existing therapies. Rather than seeking to discover
novel drug candidates through early stage research activities,
OctoPlus focuses on the development of longer acting, controlled
release versions of known protein therapeutics, other drugs, and
vaccines on behalf of its clients.
The clinically most advanced product incorporating our technology is
Biolex Therapeutics' lead product Locteron, a controlled release
formulation of interferon alpha for the treatment of chronic
hepatitis C. Locteron is being manufactured for Biolex by OctoPlus
and is currently in Phase IIb clinical studies.
In addition, OctoPlus is a leading European provider of advanced drug
formulation and clinical scale manufacturing services to the
pharmaceutical and biotechnology industries, with a focus on
difficult-to-formulate active pharmaceutical ingredients.
OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the
symbol OCTO. For more information about OctoPlus, please visit our
website www.octoplus.nl.
This announcement is not an offer to sell or a solicitation of any
offer to buy the securities of OctoPlus (the "Securities") in the
United States or in any other jurisdiction.
The Securities have not been and will not be registered under the
U.S. Securities Act of 1933, as amended (the "Securities Act"), and
may not be offered or sold in the United States or to or for the
account or benefit of, U.S. persons (as such term is defined in
Regulation S under the Securities Act) unless registered under the
Securities Act or an exemption from such registration is available.
No public offering of Securities of OctoPlus is being made in the
United States.
This announcement does not constitute a prospectus. The prospectus
dated 20 May 2009 referred to in this press release is available in
the Investor Relations section on the Company's website and via the
website of Euronext Amsterdam (Dutch residents only).
This document may contain certain forward-looking statements relating
to the business, financial performance and results of the Company and
the industry in which it operates. These statements are based on
OctoPlus N.V.'s current plans, estimates and projections, as well as
its expectations of external conditions and events. In particular the
words "expect", "anticipate", "predict", "estimate", "project",
"plan", "may", "should", "would", "will", "intend", "believe" and
similar expressions are intended to identify forward-looking
statements. We caution investors that a number of important factors,
and the inherent risks and uncertainties that such statements
involve, could cause actual results or outcomes to differ materially
from those expressed in any forward-looking statements. In the event
of any inconsistency between an English version and a Dutch version
of this document, the English version will prevail over the Dutch
version.
This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.